Nafarelin therapy in endometriosis: Long-term effects on bone mineral density

This publication has 21 references indexed in Scilit:

• Total and regional bone mineral content in women treated with GnRH agonists
  Calcified Tissue International, 1993
• An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial
  Journal of Clinical Endocrinology & Metabolism, 1993
• Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: The estrogen threshold hypothesis
  American Journal of Obstetrics and Gynecology, 1990
• Bone Mass Reduction after Estrogen Deprivation by Long-Acting Gonadotropin-Releasing Hormone Agonists and Its Relation to Pretreatment Serum Concentrations of 1,25-Dihydroxyvitamin D₃
  Journal of Clinical Endocrinology & Metabolism, 1990
• Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density
  Maturitas, 1989
• Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma
  Human Reproduction, 1989
• Pituitary-Ovarian Responses to Nafarelin Testing in the Polycystic Ovary Syndrome
  New England Journal of Medicine, 1989
• Differential Suppression of Testosterone and Estradiol in Hirsute Women With the Superactive Gonadotropin-Releasing Hormone Agonist Leuprolide*
  Journal of Clinical Endocrinology & Metabolism, 1988
• New Therapy for Endometriosis
  New England Journal of Medicine, 1988
• Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis
  New England Journal of Medicine, 1988